112 related articles for article (PubMed ID: 31879046)
1. TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Qian J; Meng H; Lv B; Wang J; Lu Y; Li W; Zhao S
Pathol Res Pract; 2020 Mar; 216(3):152703. PubMed ID: 31879046
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
3. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.
Mihashi Y; Kimura S; Iwasaki H; Oshiro Y; Takamatsu Y; Kawauchi S; Shimajiri S; Ishizuka K; Takeshita M
Diagn Pathol; 2021 Nov; 16(1):101. PubMed ID: 34742294
[TBL] [Abstract][Full Text] [Related]
4. TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Zhao S; Sun M; Meng H; Ji H; Liu Y; Zhang M; Li H; Li P; Zhang Y; Zhang Q
Cancer Manag Res; 2019; 11():4743-4756. PubMed ID: 31191027
[No Abstract] [Full Text] [Related]
5. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
6. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
[TBL] [Abstract][Full Text] [Related]
7. High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.
Qian J; Meng H; Lv B; Wang J; Lu Y; Su L; Zhao S; Li W
J Cancer; 2020; 11(1):57-68. PubMed ID: 31892973
[No Abstract] [Full Text] [Related]
8. The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma.
Sun M; Su W; Qian J; Meng H; Ji H; Liu Y; Zhang Y; Li W; Zhang Q; Zhao S
Leuk Lymphoma; 2019 Nov; 60(11):2646-2657. PubMed ID: 31017033
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in peripheral T-cell lymphomas is not related to either
Manso R; Rodríguez-Perales S; Torres-Ruiz R; Santonja C; Rodríguez-Pinilla SM
Leuk Lymphoma; 2021 Jul; 62(7):1648-1656. PubMed ID: 33550887
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.
Yamashita D; Shimada K; Kohno K; Kogure Y; Kataoka K; Takahara T; Suzuki Y; Satou A; Sakakibara A; Nakamura S; Asano N; Kato S
Pathol Int; 2020 Aug; 70(8):513-522. PubMed ID: 32424876
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract][Full Text] [Related]
15. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.
López-Guillermo A; Cid J; Salar A; López A; Montalbán C; Castrillo JM; González M; Ribera JM; Brunet S; García-Conde J; Fernández de Sevilla A; Bosch F; Montserrat E
Ann Oncol; 1998 Aug; 9(8):849-55. PubMed ID: 9789607
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma].
Huang HQ; Pan ZH; Lin XB; Wang BF; Hou JH; Zhang Y; Wu QL
Ai Zheng; 2006 Dec; 25(12):1517-23. PubMed ID: 17166378
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis in PTCL-NOS with CADM1 expression.
Kato T; Miyoshi H; Kobayashi S; Yoshida N; Imaizumi Y; Seto M; Uchimaru K; Miyazaki Y; Ohshima K
Virchows Arch; 2017 Nov; 471(5):659-666. PubMed ID: 28940014
[TBL] [Abstract][Full Text] [Related]
18. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
[TBL] [Abstract][Full Text] [Related]
19. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
20. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]